Loading
Immature immune cells that tumours summon to switch off T cells. Their numbers in blood predict worse immunotherapy outcomes.
Granulocytic (PMN-MDSC) and monocytic (M-MDSC) subsets; suppress T cells via arginase, iNOS, ROS, and PD-L1. Expanded by G-CSF, IL-6, and VEGF from tumours. Targets under study: CXCR2, STAT3, arginase inhibitors, PI3Kγ; also depleted by some chemotherapies (gemcitabine, 5-FU) and inhibited by PDE5 inhibitors in pilot trials.
In plain words · The signal tumours use to grow their own blood supply. Blocking it starves tumours and, surprisingly, helps immunotherapy work.
Showing the target this term concerns: VEGF / VEGFR.
Shares Macrophage, Nutrient competition & metabolic immunosuppression, Myeloid suppression: TAMs, MDSCs & don't-eat-me signals, Tumour microenvironment (TME).
Shares The pre-metastatic niche, Complement in cancer, Nutrient competition & metabolic immunosuppression, Myeloid suppression: TAMs, MDSCs & don't-eat-me signals.
Shares Myeloid suppression: TAMs, MDSCs & don't-eat-me signals, Tumour microenvironment (TME), PD-L1.
Shares Tumour microenvironment (TME), PD-L1.
Shares Myeloid suppression: TAMs, MDSCs & don't-eat-me signals, Tumour microenvironment (TME).
Shares Complement in cancer, Myeloid suppression: TAMs, MDSCs & don't-eat-me signals.
Shares Tumour microenvironment (TME), PD-L1.
Shares Nutrient competition & metabolic immunosuppression, PD-L1.